Pfizer UK appeals generic Lyrica ruling as patent trial nears
This article was originally published in Scrip
The launch by Actavis of a generic version of Pfizer's Lyrica (pregabalin) in the UK would not infringe a patent held by Warner-Lambert (part of the Pfizer group) on one of the three uses for which Lyrica is approved, a judge at the High Court has ruled.
You may also be interested in...
A new project devised by Pfizer and the Wellcome Trust aims to tackle antimicrobial resistance (AMR) in four sub-Saharan African countries by using real world data to track resistance patterns and allow patients to be treated more successfully. Wellcome’s Gemma Buckland-Merrett explains how the project will work and how it could help other industry partners and governments to generate valuable data in the fight against AMR.
As the US snaps up most supplies of remdesivir, the EU says it is committed to ensuring global access to coronavirus medicines and international donors have been asked to pledge more money to pay for vaccines, medicines and tests. The past week has also seen some ups and downs for trials of various products for the treatment or prevention of COVID-19.
A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.